PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
N.N. Alexandrov National Cancer Centre
N.N. Alexandrov National Cancer Centre
National Cancer Center, Korea
Taipei Veterans General Hospital, Taiwan
Shanghai Gynecologic Oncology Group
National Cancer Center, Korea
Azienda USL Reggio Emilia - IRCCS
Ankara Etlik City Hospital
Ankara Etlik City Hospital
Azienda USL Reggio Emilia - IRCCS
NHS Grampian
Tel-Aviv Sourasky Medical Center
Shanghai Gynecologic Oncology Group
Shanghai Gynecologic Oncology Group
Sheikh Zayed Medical College
Shanghai Gynecologic Oncology Group
Shanghai Gynecologic Oncology Group
Turku University Hospital
Sorlandet Hospital HF
Turku University Hospital
Bakirkoy Dr. Sadi Konuk Research and Training Hospital
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
National Cancer Center, Japan
Fujian Cancer Hospital
Sheba Medical Center
Queensland Centre for Gynaecological Cancer
Fujian Cancer Hospital
Zagazig University
NHS Grampian
Shanghai Gynecologic Oncology Group
Vastra Gotaland Region
Sheba Medical Center
Instituto de Seguridad Social del Estado de Mexico y Municipios
Henan Cancer Hospital
Sheba Medical Center
Hillel Yaffe Medical Center
Anhui Provincial Hospital
Shanghai Gynecologic Oncology Group
Shanghai Gynecologic Oncology Group
Hillel Yaffe Medical Center
Medical Research Council
Sheba Medical Center
Queensland Centre for Gynaecological Cancer
Queensland Centre for Gynaecological Cancer
National Cancer Center, Korea
National Cancer Center, Korea
Medical Research Council
Turku University Hospital
National Institute of Cancerología